Smad3 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast Transition.
Adenocarcinoma of Lung
/ genetics
Animals
Cancer-Associated Fibroblasts
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ genetics
Disease Models, Animal
Lung Neoplasms
/ genetics
Macrophages
/ metabolism
Mice
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, Nude
Mice, SCID
Myofibroblasts
/ metabolism
Signal Transduction
/ genetics
Smad3 Protein
/ genetics
Tumor Microenvironment
/ genetics
Smad3
cancer-associated fibroblasts
macrophage-myofibroblast transition
tumor microenvironment
tumor-associated macrophages
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
24
09
2021
received:
26
03
2021
pubmed:
19
11
2021
medline:
15
3
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Cancer-associated fibroblasts (CAFs) are important in tumor microenvironment (TME) driven cancer progression. However, CAFs are heterogeneous and still largely underdefined, better understanding their origins will identify new therapeutic strategies for cancer. Here, the authors discovered a new role of macrophage-myofibroblast transition (MMT) in cancer for de novo generating protumoral CAFs by resolving the transcriptome dynamics of tumor-associated macrophages (TAM) with single-cell resolution. MMT cells (MMTs) are observed in non-small-cell lung carcinoma (NSCLC) associated with CAF abundance and patient mortality. By fate-mapping study, RNA velocity, and pseudotime analysis, existence of novel macrophage-lineage-derived CAF subset in the TME of Lewis lung carcinoma (LLC) model is confirmed, which is directly transited via MMT from M2-TAM in vivo and bone-marrow-derived macrophages (BMDM) in vitro. Adoptive transfer of BMDM-derived MMTs markedly promote CAF formation in LLC-bearing mice. Mechanistically, a Smad3-centric regulatory network is upregulated in the MMTs of NSCLC, where chromatin immunoprecipitation sequencing(ChIP-seq) detects a significant enrichment of Smad3 binding on fibroblast differentiation genes in the macrophage-lineage cells in LLC-tumor. More importantly, macrophage-specific deletion and pharmaceutical inhibition of Smad3 effectively block MMT, therefore, suppressing the CAF formation and cancer progression in vivo. Thus, MMT may represent a novel therapeutic target of CAF for cancer immunotherapy.
Identifiants
pubmed: 34791825
doi: 10.1002/advs.202101235
pmc: PMC8728853
doi:
Substances chimiques
Smad3 Protein
0
Smad3 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2101235Subventions
Organisme : Research Grants Council of Hong Kong
ID : 14111720
Organisme : Research Grants Council of Hong Kong
ID : 14111019
Organisme : Research Grants Council of Hong Kong
ID : 14121816
Organisme : Research Grants Council of Hong Kong
ID : 14117418
Organisme : Research Grants Council of Hong Kong
ID : 14104019
Organisme : Research Grants Council of Hong Kong
ID : C7018-16G
Organisme : Research Grants Council of Hong Kong
ID : 14106518
Organisme : Innovation and Technology Fund of Hong Kong
ID : ITS/068/18
Organisme : Faculty Innovation Award
ID : 4620528
Organisme : Direct Grant for Research CUHK
ID : 4054386
Organisme : Direct Grant for Research CUHK
ID : 4054440
Organisme : Lui Che Woo Institute of Innovative Medicine
ID : CARE program
Organisme : The Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology
ID : 2019B121205005
Informations de copyright
© 2021 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Nat Commun. 2018 Jul 27;9(1):2951
pubmed: 30054470
Kidney Int. 2018 Jan;93(1):173-187
pubmed: 29042082
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20741-20752
pubmed: 32788346
J Cell Sci. 2014 Mar 1;127(Pt 5):1079-91
pubmed: 24424023
Sci Adv. 2020 Jun 05;6(23):eaaz6105
pubmed: 32548260
Cancer Res. 2017 Sep 15;77(18):5142-5157
pubmed: 28687621
Nature. 2013 Jun 13;498(7453):236-40
pubmed: 23685454
Cell Death Dis. 2016 Dec 1;7(12):e2495
pubmed: 27906172
Nat Neurosci. 2019 May;22(5):729-740
pubmed: 30962630
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32487570
J Am Coll Cardiol. 2019 Dec 24;74(25):3124-3135
pubmed: 31856969
J Vis Exp. 2018 Jan 9;(131):
pubmed: 29364233
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Am J Pathol. 2009 Jul;175(1):132-47
pubmed: 19528348
Diabetes. 2019 Jul;68(7):1485-1498
pubmed: 31048367
Cancer Immunol Res. 2014 Feb;2(2):121-6
pubmed: 24778275
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Int J Oncol. 2015 Aug;47(2):437-45
pubmed: 26094681
Oncotarget. 2016 Feb 23;7(8):8809-22
pubmed: 26684242
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):220-233
pubmed: 33086870
Cancer Res. 2018 Oct 15;78(20):5891-5900
pubmed: 30104241
Cancer Res. 2020 Jan 15;80(2):276-290
pubmed: 31694906
Nucleic Acids Res. 2014 Aug;42(14):8845-60
pubmed: 25053837
EMBO J. 1999 Mar 1;18(5):1280-91
pubmed: 10064594
Nature. 2013 Jul 25;499(7459):491-5
pubmed: 23863940
J Pathol. 2018 Aug;245(4):468-477
pubmed: 29732570
J Cell Mol Med. 2021 Oct;25(20):9805-9813
pubmed: 34514726
J Clin Invest. 2018 Jun 1;128(6):2356-2369
pubmed: 29708510
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Am J Pathol. 2020 Apr;190(4):886-899
pubmed: 32035062
Lung Cancer. 2018 Dec;126:64-71
pubmed: 30527194
Science. 2018 May 18;360(6390):758-763
pubmed: 29622724
J Pathol. 2016 Oct;240(2):211-23
pubmed: 27425378
Kidney Int. 2017 Mar;91(3):587-602
pubmed: 28017324
PLoS One. 2015 Aug 07;10(8):e0134965
pubmed: 26252379
Gastric Cancer. 2016 Oct;19(4):1052-1065
pubmed: 26621525
Oncol Lett. 2017 Sep;14(3):2611-2620
pubmed: 28927027
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
J Biol Chem. 2003 Apr 4;278(14):12384-9
pubmed: 12531888
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Mol Ther Oncolytics. 2021 Aug 25;23:26-37
pubmed: 34589582
J Exp Med. 2018 Dec 3;215(12):3075-3093
pubmed: 30470719
Cancer Res. 2018 Sep 1;78(17):4929-4942
pubmed: 29967265
Adv Sci (Weinh). 2022 Jan;9(1):e2101235
pubmed: 34791825
J Pathol. 2017 Feb;241(3):313-315
pubmed: 27753093
Science. 2014 Jan 10;343(6167):193-6
pubmed: 24408435
Oncogene. 2018 Dec;37(49):6327-6340
pubmed: 30038267
J Am Soc Nephrol. 2017 Jul;28(7):2053-2067
pubmed: 28209809
Cancer Immunol Res. 2020 Aug;8(8):1004-1017
pubmed: 32532809
Nat Commun. 2017 Mar 06;8:14677
pubmed: 28262747